Invesco India Pharma and Healthcare Fund
Invesco India Pharma and Healthcare Fund (Direct, Growth): Not rated by saplin yet. Expense ratio 1.91%. NAV ₹10.53 on 11 Nov 2026.
Loading the full analysis…
Invesco India Pharma and Healthcare Fund (Direct, Growth): Not rated by saplin yet. Expense ratio 1.91%. NAV ₹10.53 on 11 Nov 2026.
Loading the full analysis…
The Direct plan's total expense ratio is 1.91% a year, against a median of 1.04% for sectoral/thematic funds. The Regular plan costs more because it pays a distributor's commission.
Aditya Khemani (since 7 Sept 2026).
Apollo Hospitals Enterprise 9.08%, Divi's Laboratories 8.74%, Max Healthcare Institute 8.59%, Sai Life Sciences 8.49%, Sun Pharmaceutical Industries 8.31% of the portfolio, as of 31 Oct 2026.
About ₹111 cr (AMFI's average for the latest quarter).